Floatz logo

PANITUMUMAB

Dementia

Nottingham University Hospitals NHS Trustmonoclonal_antibodyN/ADormant
D
30/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
15/ 100
Competitive Position
81/ 100

Competitive context

40 Active assets in the Dementia cohort.

Asset / SponsorPhaseRating
Risperdal
Hannover Medical School
Phase 4BBB
Sra-333
The University of Texas Health Science Center at San Antonio
Phase 4BBB
CITALOPRAM
Hannover Medical School
Phase 4BBB
Namenda
Zealand University Hospital
Phase 4BB
Cipralex
Ohio State University
Phase 4BB

View all 50 →

Same molecule, other indications

PANITUMUMAB is also rated in:

neoplasmDormant
BBB
Indicative ·
73 / 100
View asset →
colorectal cancerDormant
BB
Indicative ·
70 / 100
View asset →
malignant pancreatic neoplasmDormant
BB
Indicative ·
68 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →